Australian diagnostics company HealthLinx Limited, along with researchers at the University of Liverpool, have just gotten word from the journal Clinical Science that their manuscript detailing the identification of a novel biomarker in ovarian cancer patients has been accepted for publication.
This means the company is now cleared to reveal the biomarker: anterior gradient protein 2 (AGR2). HealthLinx says its performance will be further tested in a forthcoming international biomarker study led by the company. Based on early data, however, this biomarker could increase the performance of the company's OvPlex diagnostic test to greater than 97 percent accuracy.
Here … Read more